Clinical Trial Update: Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial reporting efficacy and safety of subcutaneous secukinumab in adults with moderate to severe scalp psoriasis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scalp Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Scalp Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-02-28